Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900976 · ClinicalTrials.gov registry record · Phase 2
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
A Phase 2 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 20
- Study locations
NCT02900976: Completed Phase 2 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, sponsored by Children's Oncology Group.
NCT02900976 is a Phase 2 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder that has completed, run by Children's Oncology Group. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02900976, a Phase 2 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 20
- Study locations
Study Summary
This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. LMP-specific T-cells are special immune system cells trained to recognize proteins found on post-transplant lymphoproliferative disorder tumor cells if they are infected with Epstein-Barr virus. Giving rituximab and LMP-specific T-cells may work better in treating pediatric organ recipients with post-transplant lymphoproliferative disorder than rituximab alone.
Primary Outcome
The percentage of patients assigned to Arm LMP-TC who had a suitable LMP-specific T-cell product, were treated within two weeks of the expected start date, and received both weekly doses in a cooperative multi-institutional setting. A statistical analysis was planned, but not performed because accrual was stopped early and the sample size required for the analysis was not reached.
Conditions Studied
Interventions
- BIOLOGICAL Rituximab
- BIOLOGICAL Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes
Study Locations (20)
California
- Loma Linda University Medical Center - Loma Linda
- Children's Hospital Los Angeles - Los Angeles
- Mattel Children's Hospital UCLA - Los Angeles
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- UCSF Medical Center-Mission Bay - San Francisco
Florida
- UF Health Cancer Institute - Gainesville - Gainesville
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
Minnesota
- University of Minnesota/Masonic Cancer Center - Minneapolis
- Mayo Clinic in Rochester - Rochester
Alabama
- Children's Hospital of Alabama - Birmingham
Arizona
- Phoenix Childrens Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the finished NCT02900976 record still lists
NCT02900976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 7 conditions, with Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT02900976 names 20 study sites across 14 states, led by California, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02900976 about?
NCT02900976 is a clinical study titled "Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder". This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder. Rituximab is a monoclon...
What is the current status of trial NCT02900976?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2017-03-22. Estimated completion is 2025-12-31.
What conditions does trial NCT02900976 study?
This clinical trial studies the following conditions: Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder.
What interventions are being tested in trial NCT02900976?
The interventions under investigation include: Rituximab (BIOLOGICAL), Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02900976?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02900976 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02900976's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI